We are excited to share that Fusix Biotech is one of winners of the 2023 Nucleate Venture Prize funded by BlueYard Capital. BlueYard’s strategy around biology is based on the premise that humankind’s ability to engineer and understand biology will not only fundamentally transform how we diagnose, treat, and manage disease, but also reinvent how we produce new materials and the food required to support human life and sustain our planet. In recognition of these step-function changes, over the last years, we have backed a dozen companies in the space — ranging from cellular reprogramming to combat aging to sustainable materials produced in microbes.
